Work from noted gene therapy researcher Savio Woo under scrutiny with slew of retractions

Research from the lab of Savio Woo, a leading U.S. gene therapy scientist, has come into question with the retraction by major journals of at least four of his articles.

The papers, which appeared in the Proceedings of the National Academy of Sciences, the Journal of the National Cancer Institute and Human Gene Therapy, involve findings published between 2005 and 2009, address various aspect of gene therapy. Two of the articles boasted of potential breakthroughs, and even a possible cure, for diseases with extremely high rates of mortality.

The study in JNCI, for example, reported the finding of a genetically modified bacterium that showed promise for the treatment of pancreatic cancer, a particularly lethal malignancy, and other tumor types. Another, published in 2005 in PNAS, claimed to have discovered a possible cure for phenylketonuria, or PKU, in mice—a finding that was cited more than 30 times and trumpeted in the media.

However, in a retraction notice issued this month, Woo wrote that: Continue reading Work from noted gene therapy researcher Savio Woo under scrutiny with slew of retractions

What happens after a retraction for falsified data? An example from Endocrinology

In the world of scientific misconduct, it’s often worth keeping track of what happens to scientists whose papers were retracted because of falsified or otherwise fraudulent results.

Take the case of Hung-Shu Chang. Last week, the the federal Office of Research Integrity announced that it had closed its investigation into the scientist’s misdeeds. Chang was a visiting postdoctoral researcher from Taiwan who in 2005 had come to the renowned Skinner Laboratory at Washington State University to study the effects of endocrine disruptors — a class of compounds that includes BPA and which have been shown to disrupt the action of hormones — on sex cells.

Chang was accused of falsifying data in a 2006 paper in Endocrinology — later retracted — reporting the damaging effects of vinclozolin, a fungicide used to protect vineyards, on the genetic integrity of sperm cells.

According to federal and university investigators, Chang, who has since returned to Taiwan, “fabricated and falsified data” central to the authors’ claim that vinclozolin could alter sperm in such a way that the mutations could cause disease in future generations. Such mutations are referred to as epigenetic changes. Continue reading What happens after a retraction for falsified data? An example from Endocrinology

Update on stem cell-cancer link retraction: Why not everyone signed, and why authors ended up in another journal first

Last month, we wrote about the retraction of a 2005 paper suggesting that some adult stem cells might give rise to cancer. That, of course, would be a problem if researchers tried treating heart disease and other conditions with them. The paper’s authors retracted it, however, when it became clear that instead of being transformed — that’s the scientific word for “became cancerous” — the cells had simply become contaminated and overgrown with tumor cells used in research.

We had some questions for the authors of the original paper, and for the editor of the journal. Last week, we heard back from one of the paper’s authors, Javier Garcia-Castro, who had been on vacation without Internet access for weeks. In an email to Retraction Watch, Garcia-Castro wrote: Continue reading Update on stem cell-cancer link retraction: Why not everyone signed, and why authors ended up in another journal first

Science wants “reactome array” enzyme chip authors to retract paper

Following an investigation into an October 2009 study in Science that claimed to have proven the ability of a device to measure all of the enzyme activity in a cell at a particular time, the journal has asked the study’s authors to retract the paper, Science‘s news blog, ScienceInsider, reported on Friday.

The move comes after Bruce Alberts, Science‘s editor in chief, issued an Editorial Expression of Concern in December in response to concerns raised by other scientists

to alert our readers to thefact that serious questions have been raised about the methodsand data presented in this article. The questions focus in particularon the synthesis of the dye-labeled metabolites that are centralto the microarray technique. In addition, the spectroscopicdata the authors cite in support of their claim were not postedto the Bangor University School of Biological Sciences Web siteat the time of publication, despite the authors’ indicationin the Supporting Online Material that the data would be soposted. In response to inquiries from Science, the authors haveprovided new descriptions of the synthetic methods that differsubstantially from those in their published article. Based onour original concerns and the authors’ response, Science hasrequested evaluation of the original data and records by officialsat the authors’ institutions: These officials have agreed toundertake this task.

That evaluation, reported late last month by Nature, concluded Continue reading Science wants “reactome array” enzyme chip authors to retract paper